Greater Combined Reductions of HbA(1c) ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

INTRODUCTION: A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA(1c) (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators. METHODS: In the PIONEER trials, peopl...

Descripción completa

Detalles Bibliográficos
Autores principales: Dungan, Kathleen M., Bardtrum, Lars, Christiansen, Erik, Eliasson, Johanna, Mellbin, Linda, Woo, Vincent C., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299987/
https://www.ncbi.nlm.nih.gov/pubmed/37256503
http://dx.doi.org/10.1007/s13300-023-01413-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299987/
https://www.ncbi.nlm.nih.gov/pubmed/37256503
http://dx.doi.org/10.1007/s13300-023-01413-5

Ejemplares similares